vs
GE医疗（CCRN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
GE医疗的季度营收约是Orthofix Medical Inc.的1.1倍（$236.8M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -35.0%，领先34.0%），Orthofix Medical Inc.同比增速更快（2.0% vs -23.6%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $16.1M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -21.0%）
GE医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，品牌标识为GE HealthCare。公司主要业务分为四大板块：包含分子影像、CT、磁共振、妇科筛查及X光设备的医学影像业务、超声业务，以及聚焦远程患者监测、麻醉呼吸护理、心脏诊断、婴幼儿护理的患者护理解决方案业务，此外还开展医药相关业务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CCRN vs OFIX — 直观对比
营收规模更大
CCRN
是对方的1.1倍
$219.9M
营收增速更快
OFIX
高出25.6%
-23.6%
净利率更高
OFIX
高出34.0%
-35.0%
自由现金流更多
OFIX
多$698.0K
$16.1M
两年增速更快
OFIX
近两年复合增速
-21.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $236.8M | $219.9M |
| 净利润 | $-82.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -30.2% | 0.2% |
| 净利率 | -35.0% | -1.0% |
| 营收同比 | -23.6% | 2.0% |
| 净利润同比 | -2109.7% | 92.4% |
| 每股收益（稀释后） | $-2.56 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCRNOFIX
| Q4 25 | $236.8M | $219.9M | ||
| Q3 25 | $250.1M | $205.6M | ||
| Q2 25 | $274.1M | $203.1M | ||
| Q1 25 | $293.4M | $193.6M | ||
| Q4 24 | $309.9M | $215.7M | ||
| Q3 24 | $315.1M | $196.6M | ||
| Q2 24 | $339.8M | $198.6M | ||
| Q1 24 | $379.2M | $188.6M |
净利润CCRNOFIX
| Q4 25 | $-82.9M | $-2.2M | ||
| Q3 25 | $-4.8M | $-22.8M | ||
| Q2 25 | $-6.7M | $-14.1M | ||
| Q1 25 | $-490.0K | $-53.1M | ||
| Q4 24 | $-3.8M | $-29.1M | ||
| Q3 24 | $2.6M | $-27.4M | ||
| Q2 24 | $-16.1M | $-33.4M | ||
| Q1 24 | $2.7M | $-36.0M |
毛利率CCRNOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | 20.4% | 72.2% | ||
| Q2 25 | 20.4% | 68.7% | ||
| Q1 25 | 20.0% | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | 20.4% | 68.7% | ||
| Q2 24 | 20.8% | 67.8% | ||
| Q1 24 | 20.4% | 67.5% |
营业利润率CCRNOFIX
| Q4 25 | -30.2% | 0.2% | ||
| Q3 25 | -2.4% | -8.3% | ||
| Q2 25 | -2.1% | -7.9% | ||
| Q1 25 | -0.3% | -25.2% | ||
| Q4 24 | -1.1% | -5.3% | ||
| Q3 24 | 0.9% | -9.6% | ||
| Q2 24 | -5.7% | -12.5% | ||
| Q1 24 | 0.8% | -15.6% |
净利率CCRNOFIX
| Q4 25 | -35.0% | -1.0% | ||
| Q3 25 | -1.9% | -11.1% | ||
| Q2 25 | -2.4% | -6.9% | ||
| Q1 25 | -0.2% | -27.4% | ||
| Q4 24 | -1.2% | -13.5% | ||
| Q3 24 | 0.8% | -13.9% | ||
| Q2 24 | -4.7% | -16.8% | ||
| Q1 24 | 0.7% | -19.1% |
每股收益（稀释后）CCRNOFIX
| Q4 25 | $-2.56 | $-0.05 | ||
| Q3 25 | $-0.15 | $-0.57 | ||
| Q2 25 | $-0.20 | $-0.36 | ||
| Q1 25 | $-0.02 | $-1.35 | ||
| Q4 24 | $-0.13 | $-0.76 | ||
| Q3 24 | $0.08 | $-0.71 | ||
| Q2 24 | $-0.47 | $-0.88 | ||
| Q1 24 | $0.08 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $108.7M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $322.8M | $450.0M |
| 总资产 | $449.0M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCRNOFIX
| Q4 25 | $108.7M | $82.0M | ||
| Q3 25 | $99.1M | $62.9M | ||
| Q2 25 | $81.2M | $65.6M | ||
| Q1 25 | $80.7M | $58.0M | ||
| Q4 24 | $81.6M | $83.2M | ||
| Q3 24 | $64.0M | $30.1M | ||
| Q2 24 | $69.6M | $26.4M | ||
| Q1 24 | $5.2M | $27.0M |
总债务CCRNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CCRNOFIX
| Q4 25 | $322.8M | $450.0M | ||
| Q3 25 | $408.1M | $442.5M | ||
| Q2 25 | $412.2M | $458.3M | ||
| Q1 25 | $418.2M | $458.3M | ||
| Q4 24 | $419.0M | $503.1M | ||
| Q3 24 | $424.7M | $525.9M | ||
| Q2 24 | $433.3M | $546.0M | ||
| Q1 24 | $462.4M | $570.3M |
总资产CCRNOFIX
| Q4 25 | $449.0M | $850.6M | ||
| Q3 25 | $538.2M | $832.6M | ||
| Q2 25 | $553.8M | $837.2M | ||
| Q1 25 | $576.2M | $823.1M | ||
| Q4 24 | $589.3M | $893.3M | ||
| Q3 24 | $597.4M | $867.9M | ||
| Q2 24 | $602.9M | $882.0M | ||
| Q1 24 | $648.4M | $906.0M |
负债/权益比CCRNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $16.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 6.8% | 7.6% |
| 资本支出强度资本支出/营收 | 0.9% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.1M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CCRNOFIX
| Q4 25 | $18.2M | $27.7M | ||
| Q3 25 | $20.1M | $12.4M | ||
| Q2 25 | $4.2M | $11.6M | ||
| Q1 25 | $5.7M | $-18.4M | ||
| Q4 24 | $24.2M | $23.7M | ||
| Q3 24 | $7.5M | $11.7M | ||
| Q2 24 | $82.4M | $9.0M | ||
| Q1 24 | $6.0M | $-18.6M |
自由现金流CCRNOFIX
| Q4 25 | $16.1M | $16.8M | ||
| Q3 25 | $17.9M | $2.5M | ||
| Q2 25 | $2.3M | $4.5M | ||
| Q1 25 | $3.8M | $-25.1M | ||
| Q4 24 | $21.7M | $15.2M | ||
| Q3 24 | $6.3M | $6.3M | ||
| Q2 24 | $79.6M | $-360.0K | ||
| Q1 24 | $3.8M | $-29.1M |
自由现金流率CCRNOFIX
| Q4 25 | 6.8% | 7.6% | ||
| Q3 25 | 7.2% | 1.2% | ||
| Q2 25 | 0.8% | 2.2% | ||
| Q1 25 | 1.3% | -13.0% | ||
| Q4 24 | 7.0% | 7.0% | ||
| Q3 24 | 2.0% | 3.2% | ||
| Q2 24 | 23.4% | -0.2% | ||
| Q1 24 | 1.0% | -15.4% |
资本支出强度CCRNOFIX
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 0.9% | 4.8% | ||
| Q2 25 | 0.7% | 3.5% | ||
| Q1 25 | 0.6% | 3.5% | ||
| Q4 24 | 0.8% | 4.0% | ||
| Q3 24 | 0.4% | 2.7% | ||
| Q2 24 | 0.8% | 4.7% | ||
| Q1 24 | 0.6% | 5.6% |
现金转化率CCRNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
